Understanding Drug Resistance in Lung Cancer
Author Information
Author(s): Ma Yuhong, Zhang Feng, Li Jin, Li Juan, Li Yanhua
Primary Institution: The Second Affiliated Hospital of Dalian Medical University, Dalian, China
Hypothesis
Can the phosphorylation state be altered by glycosylation to improve drug resistance?
Conclusion
Research on EGFR glycosylation is crucial for targeted NSCLC treatment and will become a research direction for identifying potential targets related to regulating TKI drug sensitivity.
Supporting Evidence
- EGFR is the main target for therapy in non-small cell lung cancer (NSCLC).
- Drug resistance to EGFR-TKI therapy is a significant challenge in treating NSCLC.
- Phosphorylation and glycosylation are key posttranslational modifications that affect EGFR function.
Takeaway
This study looks at how changes in proteins can help lung cancer treatments work better, especially when the cancer becomes resistant to drugs.
Methodology
The review summarizes phosphorylation, glycosylation, and the crosstalk between these processes in the context of EGFR-TKI resistance.
Limitations
The study primarily focuses on first-generation TKI drugs, with limited insights into third-generation TKI drugs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website